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KETIDAKSTABILAN MIKROSATELIT DAN KEHILANGAN 
HETEROZIGOSITI PADA KARSINOMA SEL SKUAMOSA MULUT DALAM 
POPULASI MALAYSIA 
 
ABSTRAK 
 
Kehilangan heterozigositi (KH) dan ketidakstabilan mikrosatelit (KM) telah 
didokumentasikan sebagai peristiwa penting dalam perkembangan karsinoma sel 
skuamosa mulut. Lima penanda mikrosatelit iaitu D3S192, D3S966, D3S647, D3S1228 
dan D3S659 dipilih pada kromosom 3p kerana perubahan berfrekuensi tinggi yang 
dilaporkan dalam karsinoma sel skuamosa kepala dan leher  dan penglibatan gen VHL 
(von Hippel Lindau) pada 3p25-26  dan gen FHIT (fragile histidine triad) pada 3p14.2 
terbukti dalam pelbagai jenis tumor. Sebanyak 50 sampel tisu arkib karsinoma sel 
skuamosa mulut dan tisu normal pada pesakit yang sama diambil untuk analisis status 
KH dan KM. Pada keseluruhannya, KH yang terdapat pada kromosom 3p didapati 
dalam 56 daripada 189 kes (29.6%). KH yang paling sering didapati adalah pada 
penanda D3S966 dengan 18/42 (42.8%) kes menyarankan kehadiran TSGs pada lokasi 
ini. Dalam kajian ini, didapati KM pada D3S966 paling sering terjadi iaitu 28.6% kes, 
hal ini menunjukkan kemungkinan terjadinya mutasi pada gen MMR pada lokasi ini. 
Perubahan mikrosatelit paling sering terjadi pada D3S966 (71.4%), D3S1228 (56.7%) 
dan D3S192 (41.0%). Dalam kajian ini, tiada hubungan yang signifikan didapati antara 
KH pada kromosom 3p dengan jantina, peringkat tumor dan gred perbezaan tisu. Namun 
begitu, hubungan yang signifikan didapati diantara peringkat tumor dan  perbezaan tisu 
dengan status KM dengan nilai p 0.002 dan 0.035. Terdapat juga hubungan yang 
xvi 
 
signifikan diantara perubahan mikrosatelit dengan gred berbezaan tisu dengan nilai p 
0.041.      
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MICROSATELLITE INSTABILITY AND LOSS OF HETEROZYGOSITY IN 
ORAL SQUAMOUS CELL CARCINOMA IN A MALAYSIAN POPULATION 
 
ABSTRACT 
 
Loss of heterozygosity (LOH) and microsatellite instability (MSI) have been 
documented as important events of oral squamous cell carcinoma (OSCC). Five 
microsatellite markers D3S192, D3S966, D3S647, D3S1228 and D3S659 were selected 
on chromosome 3p because of high frequency of alterations reported in head and neck 
squamous cell carcinoma and the involvement of VHL (von Hippel Lindau) at 3p25-26  
and the FHIT (fragile histidine triad) at 3p14.2 genes proven in many tumor types. A 
total of 50 archival tissue samples of OSCC and corresponding normal samples were 
analyzed for LOH and MSI status. The overall LOH for the markers selected on 3p was 
56 out of 189 informative cases (29.6%). The most frequent LOH was identified at the 
marker D3S966 which is 18/42 (42.8%) of informative cases suggesting the presence of 
putative of TSGs in this loci. In this study, we found high MSI in D3S966 which is 
28.6% of informative cases; this reveals the possibility of mutation of mismatch repair 
genes in this region. Frequent microsatellite alteration (MA) was observed in D3S966 
(71.4%), D3S1228 (56.7%) and D3S192 (41.0%). There is no significant association 
between LOH with gender, tumour stage and differentiation grades. However, there is a 
significant association between tumour stage and differentiation grades with MSI status 
in OSCC in Malaysian population with p values of 0.002 and 0.035. There is also a 
significant association between MA and differentiation grades with a p value of 0.041.      
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background of the study 
 
Oral cancer remains a serious and constant problem. It is the sixth most common cancer 
reported worldwide with estimated 405,318 new cases annually. Markedly, higher 
prevalence of oral cancer is found in some Asian populations, mainly in South Asian 
countries including India and Pakistan, where it is the most common cancer in males and 
the second most common cancer in both sexes. Geographic or regional variations in the 
prevalence of oral cancer indicate that the socio-cultural lifestyles of a population play 
an important role in oral carcinogenesis. Squamous cell carcinoma accounts for more 
than 90% of oral cancers (Iamaroon et al., 2004). 
 
In Peninsular Malaysia, Indian was the predominant ethnic group who had oral cancer in 
Kelantan, Negeri Sembilan and Perak while Kadazan/Dusun was the more prominent 
ethnic group with oral cancer in Sabah and the Iban in Sarawak. The gum area was the 
highest area for oral cancer for all the states except for Negeri Sembilan where the cheek 
mucosa is mostly affected (Zain et al., 1997). Smokeless tobacco use was involved in the 
etiology of the oral pre-cancerous and cancerous lesions. In the South Asian region, 
more than one-third of tobacco consumed is smokeless. Traditional forms like betel 
quid, tobacco with lime and tobacco tooth powder are commonly used and the use of 
new products is increasing, not only among men but also among children, teenagers, 
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women of reproductive age, medical and dental students. In India, where chewing 
tobacco is used with betel nuts and reverse smoking (placing the lit end in the mouth) is 
practiced, there is a striking incidence of oral cancer cases, which account for as many as 
50% of all cancers. While cases of oral cancers are seen in patients who do not use 
tobacco, these constitute a very small percentage of all oral cancers. Males have this 
type of cancer about twice as often as females. Tobacco products, especially smokeless 
tobacco, are a primary cause.  Females are more commonly experiencing this type of 
cancer as they use tobacco products (Khandekar et al., 2006). 
 
Squamous cell carcinomas account for 90% of all oral cancers, followed by 
adenocarcinomas and Kaposi’s sarcomas. Squamous cell carcinomas occur in all sites of 
the oral cavity, including tongue, lips, floor of the mouth, soft palate, and tonsils. 
Adenocarcinomas occur mainly in the salivary glands while Kaposi’s sarcomas mainly 
occur in the palate. Of all the anatomic sites, the tongue and floor of the mouth account 
for most of these cancers. Symptoms include tender painful lesions, wounds or sores that 
will not heal, a lump or thickened skin, a white or red patch, loose teeth or dentures, 
trouble chewing or swallowing, swelling of the jaw, and sore throat (Silverman, 1999). 
 
Inactivation of tumour suppressor genes and activation of oncogenes have been shown 
to play a role in the multi-step process of human carcinogenesis. Molecular genetic 
studies of oral squamous cell carcinoma (OSCC) have been focussed on the 
identification of tumour suppressor gene (TSG) loci and amplified oncogenes. Previous 
loss of heterozygosity (LOH) studies focussed on specific chromosome segments have 
shown frequent loss of alleles from 3p, 8p, 9p, chromosome 13 and 17p in head and 
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neck squamous cell carcinoma (HNSCC), including OSCC (Ishwad et al., 1996; Arai et 
al., 2002; Coon et al., 2004; Gao et al., 2007). A number of recent studies using 
comparative genomic hybridization (CGH) and allelotyping showed HNSCC display 
large and extensive genomic imbalances and that certain chromosome segment are lost 
more often than others. These studies confirmed the frequent deletion and LOH from 3p, 
9p, 13q, and 17p, detected in more than 50% of the cases. In addition, segmental loss in 
3q, 4p, 4q, 5q, 6p, 6q, 8p, 8q, 11q, 14q, 17q, 18q, and 20p have been shown in 
significant subsets (Weber et al., 1998). 
 
Allelic imbalances including LOH and microsatellite instability (MSI) in malignant cells 
have proven useful for mapping DNA regions potentially harboring candidate TSGs. 
Studies on somatic LOH have led to the discovery of genes, including RB 
(Retinoblastoma gene), p53, WT (Wilms tumour), CDKN2A (Cycline dependent kinase 
number 2), APC (Adenomatous polyposis coli), DPC4 (Candidate suppressor gene for 
pancreatic cancer), FHIT (Fragile histidine triad) and PTEN (Putative protein tyrosine 
phosphatase gene) (Arai et al., 2002). 
 
LOH in chromosome 3p material, in particular 3p13-p21, 3p21-23, and 3p25, is a 
common genetic change shared by several types of carcinomas. Several TSGs that have 
been mapped to these regions include two genes that have been studied for the presence 
of inactivation mutations in OSCC which is FHIT gene in 3p14.2 and VHL (von Hippel 
Lindau) gene in 3p25-26. The finding of alterations of FHIT in oral precancerous lesions 
and SCC supports the pathogenetic role of FHIT in OSCC carcinogenesis. However, 
very little evidence for the involvement of VHL in OSCC could be observed (Tsui et al., 
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2008). Previous study also identified a novel commonly deleted region on 3p21.3 
(D3S966) suggesting that unknown TSG specific to Indian and Japanese OSCC exist at 
this region (Yamamoto et al., 2007).  
 
Subsets of many types of malignancies show contraction or expansion of MSI.  MSI is 
based on the functional impairment of one of the mismatch repair (MMR) genes MLH1, 
MSH2, MSH6, or PMS2, and germline mutations in these genes predispose for the 
hereditary nonpolyposis colorectal cancer (HNPCC) syndrome.  Affected individuals are 
at an increased risk for a variety of carcinomas, not usually involving HNSCC. High-
level MSI has been reported in 10% to 15% of all colorectal cancers and is based mainly 
on hypermethylation of the MLH1 promoter. Similarly, molecular studies have revealed 
that MSI and loss of heterozygosity (LOH) occur in head and neck cancer, suggesting 
the influence of both mutator and tumour suppressor pathways in head and neck 
carcinogenesis. Identification of tumours based on MMR deficiency may become 
important for the clinical management of the disease, as there is growing evidence from 
studies on colorectal cancer that such tumours have a better prognosis on one hand, but 
do not benefit from chemotherapy on the other (Koy et al., 2008). 
 
1.2 Problem statement 
 
Stage at diagnosis is the most important prognostic indicator for OSCC. Unfortunately, 
about 50% of these cancers are identified late (stages III or IV). If lesions are detected 
when they are small, localized, and treated quickly, survival rates of 70–90% can be 
achieved. Thus, the possibility of cure depends on the time elapsed between the first 
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symptom and the beginning of the treatment. Due to the effect of field cancerization, 
patients with OSCC may suffer recurrences after the treatment or develop second 
malignant tumours at various sites (Morelatto et al., 2007). 
 
Radical surgery is the primary treatment of OSCC. High-stage disease often requires 
postoperative adjuvant radiotherapy to eliminate all residual disease and is therefore 
more distressing for patients and, unfortunately, less successful in survival when 
compared to treatment of low-stage disease, whereas patients with high-stage tumours of 
larger size and higher metastatic potential have only a 30% chance of survival at 5 years, 
patients with low-stage cancer have an 80% to 90% chance of survival. A high degree of 
clinical expertise is required to detect OSCC, and this is not widely available. The 
development of detection methods (such as blood tests) that can act as a surrogate for a 
highly skilled clinical examination would allow detection of OSCC at an early stage as 
well as monitoring response to treatment and helping to identify residual disease after 
treatment. This would significantly improve survival as treatment of early stage disease 
has been shown to be more successful (Tiziani et al., 2009). 
 
Early detection and even screening high risk populations of OSCC and precursor lesions 
is an attractive strategy to reduce the suffering of OSCC, and thus scientists engage to 
find efficient diagnosis and preclinical screening approaches. For decades, numerous 
publications on the use of oral cytology or histological manifestations as a diagnostic 
approach have been reported. In recent years, considerable progress has been made in 
understanding the genetic and proteic basis of OSCC carcinogenesis and a number of 
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specially expressed genes and proteins are proposed as biomarkers for clinical diagnosis 
(Yan et al., 2008). 
 
1.3 Justification of the study 
 
Studies on microsatellite alterations (LOH and MSI) have demonstrated genomic 
instability reflecting defective mismatch repair system and presence of putative tumour 
suppressor genes. Molecular markers allow intermediate measurement of the outcome of 
the therapy as molecular changes occur before histological changes and are essential in 
the diagnosis and management of patients with oral cancer. The selection of 
microsatellite markers D3S192, D3S647, D3S966, D3S1228, D3S659 located on 
chromosome 3p is based on their highly informative nature in OSCC (Arai et al., 2002). 
 
The incidence of OSCC varies in different parts of the world and the epidemiological 
difference and frequencies of MSI and LOH in the different population may be reflected 
at the molecular level. Several studies using different sets of microsatellite markers 
detected MSI frequencies at great diversity, ranging from 2% to 60% (Koy et al., 2008). 
Because of limited information on microsatellite alterations in OSCC in a Malaysian 
populations, the present study will provide a basis on the understanding of the different 
frequencies in which these microsatellite occur, which in turn will provide an insight 
into the molecular differences persistent in the Malaysian population. This will help in 
unravelling the genetic causes underlying the OSCC in the Malaysian population which 
will target to new interventions and clinical care directed at the molecular changes of 
cancer. 
7 
 
1.4      Objectives 
 
1.4.1 General objective 
 
The purpose of this study is to determine the percentage of microsatellite alterations on 
chromosome 3p in OSCC in a Malaysian population. 
 
1.4.2  Specific objectives 
 
1 To determine the percentage of LOH of the five microsatellite markers on 
chromosome 3p in OSCC in a Malaysian population. 
2 To determine the percentage of MSI of the five microsatellite marker on 
chromosome 3p in OSCC in a Malaysian population. 
3 To associate the percentage of LOH with the histopathological grading in the 
cancer tissue. 
4 To compare the MA between different markers selected on chromosome 3p in the 
cancer tissue. 
 
1.5     Research hypothesis 
 
Microsatellite alterations on chromosome 3p are associated with development of OSCC 
in a Malaysian population. 
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CHAPTER 2 
 
LITREATURE REVIEW 
 
2.1 Oral cancer 
 
Oral cancer is a part of a group of cancers called head and neck cancers. Oral cancer 
includes tumours of the lip, tongue, floor of the mouth and pharynx (Canto and Devesa, 
2002). OSCC accounts for 90% of all oral cancers, followed by adenocarcinomas and 
Karposi’s sarcomas (Syme et al., 2001). OSCC are thin, flat cells that look like fish 
scales when observed under the microscope. Of all the anatomic sites, the tongue and 
floor of the mouth account for most of these cancers (Figure 2.1).   
 
2.1.1 Prevalence and incidence of oral cancer  
 
OSCC is the sixth most common cancer reported worldwide with estimated 400,000 new 
cases annually (Seeram et al., 2011). Incidence rates are more than twice as high in man 
when compared to woman. Higher prevalence was found in Asian populations, mainly 
in South Asian countries including India and Pakistan where it is the most common 
cancer in males and the second most common cancer in both sexes (Iamaroon et al., 
2004). In Malaysia, mouth cancer is the 20th most common cancer for females and 
28thfor males of overall cancer incidence per 100,000 populations in the year of 2006 
(Ministry of Health, 2006). Oral cancer among the Indian males and females accounts 
for 2.5% and 7.3% respectively of all cancers. It can be ranked as 14th and 4th most 
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common cancers for the Indian males and females respectively. Hospital based data 
from different hospitals in Malaysia has shown that oral cancer is highest among ethnic 
Indians and other Bumiputras (the indigenous people of Sabah and Sarawak) followed 
by the Malay and Chinese (Ministry of Health, 2006). 
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Figure 2.1: Mouth anatomy (http:www.boddunan.com/health-a-fitness/66-
diseases/1850-what-is-mouth-cancer.html). 
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2.1.2 Risk factors of oral cancer 
 
Smokeless tobacco and alcohol use are the major causes of oral cancer. People who 
smoke and drink have 10 times more risk to get oral cancer than people who do not 
smoke and drink and 100 times greater in people who smoke and drink heavily 
(Lippman et al., 2005). The risk of oral cancer associated with smoking is both dose and 
duration dependent while smoking cessation leads to a fall in risk. Other risk factors are 
betel quid chewing, actinic radiation (sunlight exposure), immune system deficiencies, 
viral infections (Human Papilloma Virus), nutritional deficiencies, and certain oral 
condition (Canto, 2002).  
 
The incidence of oral cancer is age related, which may reflect time for the accumulation 
of genetic changes and duration of exposure to initiators and promoters (chemical and 
physical irritants, viruses and hormonal effect), cellular aging and decreased 
immunologic surveillance with aging. About 95% of all oral cancers occur in persons 
over 40 years old, and the average age at the time of diagnosis is 60 (Burket, 2003). 
 
Ethnic background is known to influence many types of cancers. For example, in 
Malaysia oral cancer in Indians is increasing at faster rate than in Chinese and Malay. 
The chronic use of betel quid (paan) in the mouth among Indian people has been 
strongly associated with an increased risk for oral cancer (Johnson, 2001). The quid 
typically consists of a betel leaf that is wrapped around a mixture of areca nut and slaked 
lime, usually with tobacco and sometimes with sweeteners and condiments. The slaked 
lime results in the release of an alkaloid from the areca nut, which produces a feeling of 
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euphoria and well-being in the user. Betel quid chewing often results in a progressive, 
scarring precancerous condition of the mouth known as oral submucous fibrosis. This 
suggests that genetic factors, differences in habits and lifestyle are strongly implicated. 
Variation in incidence rate among ethnic groups may be influenced by differences in 
exposure to carcinogenic initiator or promoter (Avon, 2004). 
 
2.1.3 Oral Carcinogenesis 
 
Oral carcinogenesis is a multistep process requiring the accumulation of multiple 
genetic, epigenetic and metabolic alterations, influenced by a patient's genetic 
predisposition as well as by environmental influences, including tobacco, alcohol, 
chronic inflammation, and viral infection (Lippman et al., 2005). OSCC development 
usually involves normal oral mucosa changing to oral dysplasia and changing to 
invasive cancer (Figure 2.2). Oral dysplasia may progress to OSCC over time and 
therefore can be considered as premalignant lesions. Dysplasia can be detected only by 
taking a biopsy of the lesion. Examining the dysplastic cells under a microscope 
(histology) indicates how severe the changes are and how likely the lesion is to become 
cancerous (Epstein et al., 2007).   
 
The two most common kinds of premalignant lesions in the oropharynx are leukoplakia 
and erythroplakia (Figure 2.3). Leukoplakia is a white or whitish lesion of the oral 
mucosa that cannot be clinicopathologically characterized as any other definable lesion. 
These lesions are usually caused by smoking and chewing snuff. About 8% of 
leukoplakias are cancerous at diagnosis or will become cancerous within 10 years if not 
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treated. Erythroplakia is a raised, red patch and may bleed if scraped. Erythroplakia is 
generally more severe than leukoplakia and has a higher chance of becoming cancerous 
over time (Waal et al., 1997). 
 
Squamous cell carcinoma is a common type of cancer account for more than 90% of all 
cancers (Figure 2.3). These cancers start in the squamous cells, which form the surface 
of many layers of the mouth and pharynx. They can invade deeper layers below the 
squamous layer. When oral cancer spreads, it usually travels through the lymphatic 
system. It can also spread to other parts of the body. For example, if oral cancer is 
spread into the lungs, the cancer cells in the lungs are actually oral cancer cells. Doctors 
sometimes call the new tumour "distant disease or metastatic” (Harrison, 2009). 
 
Molecular mechanisms underlying oral carcinogenesis remain largely unknown. 
Damage affect many chromosomes and genes, particularly TSGs and oncogenes and it is 
the accumulation of such genetic damage and the consequent disturbed cell growth and 
control, which in some instances appears to lead to carcinoma. At the moment of cancer 
detection, when malignant growth becomes macroscopically detectable, many steps 
towards a mature cancer have already taken place. In normal cells, genetic mutations 
will not lead to cancer, since DNA repair mechanisms and cell cycle checkpoints are 
actively protecting cells from becoming malignant. When mutations accumulate within 
these protective systems, a “mutator phenotype” develops and an important step towards 
cancer has been set (Kaufmann and Paules, 1996). 
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Figure 2.2: Oral cancer development (http://oralcancerfoundation.org). 
 
 
Figure 2.3: Oral cancer and precancerous lesion. (A) Leuokoplakia seen as a white 
lesion (B) Erythroplakia of the ventral tongue seen as a well demarcated red patch. (C) 
Squamous cell carcinoma seen as exophytic, papillary mass of the buccal mucosa 
(Bouquot et al., 2010). 
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2.1.4 Genetic and epigenetic alterations of oral cancer 
 
The accumulation of genetic and epigenetic alterations drives the progression of normal 
cells to dysplastic stages and to invasive cancer (Figure 2.2). Mutational and gene 
expression analysis of known TSGs and oncogenes in early tumourigenesis has provided 
insight to the role of these genes in cancer progression (Holmes et al., 2007). In recent 
years, considerable research has been made to identify the candidate TSGs that lead to 
oral cancer. Accumulation of genetic and epigenetic alterations include alteration of 
TSG such as FHIT (LOH at chromosome region 3p14), p16 (LOH at 9p21 and p16 
promoter hypermethylation), VHL (mutation and LOH at 3p25) and p53 (mutation and 
LOH at 17p) ( Arai et al., 2002, Sakamoto et al., 2004, Lippman et al., 2005, Yamamoto 
et al., 2007). 
 
p53 TSG on chromosome 17 is responsible to produce 53kDa nuclear phospoprotein, 
that binds to DNA and suppress cell growth and division. If cell repair is impossible, p53 
triggers apoptosis (programmed cell death). Mutation or LOH at p53 region will alter 
p53 protein that will predispose to develop cancer.  p53 are most common genetic 
alterations in many malignancies, including oral cancer (Conde et al., 1999). Previous 
studies have reported that inactivation of p53 gene is associated with the development of 
oral cancer (Huang et al., 1999). Aberration in p53 is an early event of oral 
carcinogenesis but it is not the only gene that is responsible and many other molecular 
events occur. 
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Mutation and LOH of VHL gene located at 3p25 are frequently seen in oral cancer. The 
VHL gene encodes 4.7kb mRNA, which is widely expressed in both fetal and adult 
tissue, such that expression of VHL transcript and protein is ubiquitous and not restricted 
to those organs affected by VHL tumours. In normal condition, VHL gene will prevent 
cells from growing and dividing too rapidly or in an uncontrolled way. In contrast, 
mutation in VHL gene will promote progression of oral cancer (Richards, 2001; 
Lippman et al., 2005) 
 
p16 also known as CDKN2A, is a tumour suppressor protein, which in humans is 
encoded by the CDKN2A gene. P16 plays an important role in regulating the cell cycle, 
and mutations in p16 increase the risk of developing a variety of cancers. Inactivation of 
p16 gene by CpG methylation is a frequent event in oral epithelial dysplasia. Latest 
study by Cao et al., (2009) reported that p16 methylation can lead to malignant 
transformation of oral epithelial dysplasia and Vairaktaris et al., (2007) also reported 
that inactivation of p16 occurs at the early stage of oral mucosal dysplasia in the 
multistep process of oral tumourigenesis. Therefore, p16 may be considered as a useful 
prognostic marker for the progression of oral cancer and is a potential biomarker for 
prediction of prognosis of mild or moderate oral epithelial dysplasia.  
 
Alteration in FHIT gene has been reported to be associated with oral carcinogenesis. 
LOH at FHIT region (3p14.2) have been found in various human malignancies including 
HNSCC, lung cancer and renal cell carcinoma (Tanimoto et al., 2000; Kujan et al., 
2006). This gene, a member of the histidine triad gene family, encodes a diadenosine 
5',5'''-P1,P3-triphosphate hydrolase involved in purine metabolism. The gene 
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encompasses the common fragile site FRA3B on chromosome 3, where carcinogen-
induced damage can lead to translocations and aberrant transcripts of this gene. In some 
tumours, particularly those associated with environmental carcinogens, alterations in the 
FHIT gene occur quite early in the development of cancer. In other cancers, FHIT 
inactivation seems to be a later event, possibly associated with progression to more 
aggressive neoplasias (Croce et al., 1999). 
 
2.1.5 Management of oral cancer 
 
Oral cancer is lethal disease with 5 years survival of less than 50%. Death owing to 
distant metastasis, once considered to be a rare feature, is now more common as a result 
of better loco regional control (Canto, 2001). Early detection is the main factor for better 
prognosis. Generally, oral cancers are curable when diagnosed and treated in localized 
stages. Clinicians’ knowledge of the early signs and symptoms of oral cancer is 
important for diagnoses and appropriate referral. To accurately detect a lesion in the 
early stages, general clinician must be familiar with where to look and what to see in 
oral cavity. The past few decades have seen an increasing knowledge in oral 
carcinogenesis as well as technology advances in the diagnosis of oral cancer. These 
include epidemiology of oral cancer, detection and early diagnosis of oral cancer, and 
treatment of patients (radiotherapy, chemotherapy, gene therapy and surgery) (Canto, 
2001). 
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2.1.5.1 Diagnosis of oral cancer  
 
Detection and early diagnosis of oral cancer involve both individual and professionals. 
Individual is responsible to detect when the first symptom appear. Dentists are the 
provider of choice to perform oral cancer examinations but unfortunately majority of 
them do not visit a dentist in a given year (Goodman et al., 1995). Thus, other health 
care providers must assume more responsibility to ensure that the public receive oral 
cancer examinations on a routine basis. Primary care physicians should know that 
targeting those at high risk is a viable and cost-effective intervention for oral cancer 
when performed as part of routine practice. Equally important, members of the public 
need to know that an examination for oral cancer is available and that they can request 
one routinely. Thus, both health care providers and the general public need to increase 
their knowledge and change their behaviors or practices (Horowitz et al., 1996). 
 
The prognosis of oral cancer is conditioned by several variables such as 
histopathological variety, degree of tumour differentiation, extension and localization of 
the primary tumour, degree of invasion of neighboring structures, presence of metastatic 
regional lymph nodes, presence of distant metastases, the choice of therapeutic modality, 
and the general health status of the patient. Once clinical signs of oral cancer are seen, a 
biopsy will be taken, followed by histopathological examination. Primary care providers 
usually refer to a specialist for the biopsy and further follow up, although several 
primary care providers may choose to biopsy the lesion. A histopathological report 
confirming invasive oral cancer will usually trigger the treatment mechanism. However, 
tumours that appear similar morphologically and histologically will show varying 
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responses when treated in identical way. Thus, the use of a new technology to diagnose 
oral cancer is needed (Brandizzi et al., 2008). 
 
While the biopsy is still required for a definite diagnosis, today several non-invasive 
methods are commercially available to aid clinicians in the diagnosis of oral cancer. 
Some of the most common methods include a method using a brush biopsy that collects 
oral cells and examining them under the microscope for signs of malignant 
transformation. The second methods which is a chemiluminescent method that uses a 
light followed by tolouidine blue application for vital tissue staining. The third method is 
a method that uses a device emitting a blue light to examine differential tissue 
fluorescence. While adjunctive techniques that are non-invasive usually lead to a high 
rate of false positive findings, they can offer significant aid in healthcare professionals 
who are highly trained with the specific method to spot high risk lesions that are either 
sub-clinical or at their very early phases (Donnell, 2008). However, the fact that they are 
used by only a fraction of dentists in the United States presents practical and logistical 
difficulties during referrals. Anecdotal reports exist about dentists who identify lesions 
and refer them to specialists for further evaluation, only to have  the specialists dismiss 
the case due to lack of ability to spot the same lesion without the use of the same 
technology at the specialists office. A systematic intervention is needed to assess the 
scientific and clinical validity of a network of healthcare professionals all using standard 
same methods, applied in a community setting (Donnell, 2008).  
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2.1.5.2 Treatment of oral cancer patients 
 
Treatment of the patients involves radiotherapy, chemotherapy and surgery. 
Contemporary radiotherapeutic treatment encompasses new forms of radiation and the 
application of sophisticated computerized methods to enhance the therapeutic 
effectiveness with an important reduction in the irradiation of normal surrounding 
tissues. This has led to an increased therapeutic dose in the tumour site and a decreased 
severity of radiation-induced injuries. Methotrexate was surpassed by platinum based 
agents with or without 5-Fluorouracil. Adjuvant and neoadjuvant schemes coupled with 
pre- or post-operative radiotherapy starting from the late 80s showed a distinct survival 
benefit over radiotherapy alone (Fuller et al., 2010). This major breakthrough was 
followed by the introduction of taxanes and the development of molecular targeted 
therapies which, during the last 5 years, have revolutionized the concept of chemo-
radiation. Induction chemotherapy and chemo-radiation coupled with epidermal growth 
factor receptor (EGFR) antagonists have proved to offer a survival benefit to patients 
with locally advanced or recurrent squamous cell carcinoma (Blackhall et al., 2005). The 
revolution in the surgical treatment of oral/head and neck cancer was the introduction of 
reconstructive techniques with both pedicled locoregional flaps and free tissue transfer 
which allow for safer and wider resections with adequate disease free margins and 
functional reconstruction of the created surgical defects (Clayman et al., 1997). There 
have been major changes in the surgical management of both clinically negative and 
clinically positive neck patients, as well as in the management of the mandible, 
especially where there is early mandibular invasion. However, modification of 
21 
 
radiotherapy, chemotherapy and surgery has not improved the survival rate of the 
patients (Clayman et al., 1997).  
 
Advances in molecular biology and genetics, and the human genome project, led to an 
explosion in deciphering oncogenes, TSGs and other genes, and their biological role in 
oral carcinogenesis. Gene therapy is one of the approaches of new treatment for oral 
cancer patients. Gene therapy can be defined as gene transfer for the purpose of treating 
human disease (Xi and Grandis, 2003). This includes the transfer of new genetic 
material as well as the manipulation of existing genetic material. This holds true 
especially for cancer cells, where dominantly activated oncogenes can be targeted. The 
transfer of genetic material may occur in vivo (where the gene is introduced into the 
body) or ex vivo (where a tumour is removed, the genetic materials delivered, and the 
cells are then re-introduced into the patient). The ex vivo approach has not been utilized 
in oral cancer because superficial lesions usually lend themselves to the direct injection 
of genetic material (Saraswathi et al., 2007). 
 
2.2 Microsatellite 
 
Microsatellite analyses include LOH and MSI, which is one of the techniques used to 
detect possible regions of TSGs and oncogenes. Microsatellites of DNA are tandem 
repeats of 1–6 nucleotides found scattered throughout the human genome. 
Microsatellites (also called simple sequence length polymorphisms: SSLPS; and short 
tandem repeat polymorphisms: STR) can be defined as tandem arrays of short stretches 
of nucleotide sequences, usually repeated between 15 and 30 times. Microsatellites 
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belong to the family of repetitive non-coding DNA sequences, which can be classified as 
follows. (i) Satellite sequences: arrays with repeat sizes ranging from 5 to 100 bp, 
characteristically organized in clusters up to 100 mega bases (Mb). (ii) Minisatellite 
sequences: arrays with repeat sizes of 15-70 bp which range in size from 0.5 to 30 
kilobases (kb). (iii) Microsatellite sequences: arrays with a repeat size of 2-6 bp, highly 
variable in size but ranging around a mean of 100 bp. Microsatellites are found in the 
euchromatin and allele sizes in populations characteristically exhibit multiple size 
classes distributed about the population mean.  Microsatellites have various applications; 
these include genome analysis, allelic imbalance analysis, population studies and 
forensic application (Koreth et al., 1996). 
 
2.2.1 Microsatellite instability 
 
Microsatellite instability in cancer cell is defined as a change that occurs in the DNA in 
which the number of repeats of microsatellites is different than the number of repeats 
that was in the DNA when it was inherited. The frequencies at which changes in repeat 
number occur at microsatellite loci are much higher than normal mutation rates, 
involving a frequent change in repeat number by one or two repeats at a time, and rare 
large changes in repeat number, representing two distinct classes of mutation at 
microsatellite loci. This slippage synthesis model can explain the relation between 
defective DNA repair and MSI seen in some disease states (Figure 2.4). It was initially 
thought that repeat sequences possessed a functional role in the genome, either directly 
via a role in gene regulation or indirectly as hot spots for recombination, their mutagenic 
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potential enhancing the long-term evolutionary potential of the species (Koreth et al., 
1996). 
 
Microsatellite instability is mostly found in association with deficiencies in DNA 
mismatch repair systems and was first described in hereditary non-polyposis colon 
cancer (HNPCC) patients. MMR genes that are related with this cancer are MLH1, 
MSH2, MSH6 and PMS2. The colorectal tumours are often classified into MSI-high 
(changes in ≥2 markers), MSI -low (exhibiting instability at one marker) or MSI-stable 
exhibiting no changes in the selected loci. MSI-high has been reported in 10%-15% of 
all colorectal cancers and is based mainly on hypermethylation of the MLH1 promoter 
(Robinson et al., 2007). Several studies using different sets of microsatellite markers 
detected MSI percentage at a great diversity ranging from 2%-60% (Koy et al., 2008). In 
oral cancer, alterations in microsatellite have been reported with variable percentage 
while the majority of studies show low percentage. Therefore, the importance of MSI in 
oral cancer is not well established, because of lack of standardized and comparable 
parameters among the so far published studies. Moreover, none of the MSI tumours has 
been found to be associated with germline mutation (Koy et al., 2008).     
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Figure 2.4: The effects of microsatellite instability on (CA)n dinucleotide tandem 
repeats. Repetitive sequences, represented by CA repeats, can slip either at the parental 
DNA or newly synthesis daughter DNA strand. This slippage can be repaired by 
mismatch repair (MMR) system. However, mutation in MMR gene make MMR enzyme 
failed from identifying this error and will leave this strand uncorrected. Consequently, 
loss of the MMR system leads to development of cancer (http://phg.mc.vanderbilt.edu/ 
content/ezlod). 
 
 
 
 
 
 
 
